MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver by Ylösmäki, Erkko et al.
MicroRNA-Mediated Suppression of Oncolytic
Adenovirus Replication in Human Liver
Erkko Ylo¨sma¨ki1, Sergio Lavilla-Alonso1, Sari Ja¨a¨maa1,2, Markus Va¨ha¨-Koskela3, Taija af Ha¨llstro¨m4,
Akseli Hemminki3, Johanna Arola5, Heikki Ma¨kisalo6, Kalle Saksela1*
1Department of Virology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland, 2Molecular Cancer Biology
Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland, 3Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory,
University of Helsinki, Helsinki, 4 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 5Department of Pathology, Haartman Institute,
University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland, 6Department of Gastrointestinal Surgery, Helsinki University Central Hospital,
Helsinki, Finland
Abstract
MicroRNAs (miRNAs) are important and ubiquitous regulators of gene expression that can suppress their target genes by
translational inhibition as well as mRNA destruction. Cell type-specific miRNA expression patterns have been successfully
exploited for targeting the expression of experimental and therapeutic gene constructs, for example to reduce pathogenic
effects of cancer virotherapy in normal tissues. In order to avoid liver damage associated with systemic or intrahepatic
delivery of oncolytic adenoviruses we have introduced the concept of suppressing adenovirus replication in hepatic cells by
inserting target elements for the liver-specific miR122 into the viral genome. Here we show using ex vivo cultured tissue
specimens that six perfectly complementary miR122 target sites in the 39 untranslated region of the viral E1A gene are
sufficient in the absence of any other genetic modifications to prevent productive replication of serotype 5 adenovirus
(Ad5) in normal human liver. This modification did not compromise the replicative capacity of the modified virus in cancer
tissue derived from a colon carcinoma liver metastasis or its oncolytic potency in a human lung cancer xenograft mouse
model. Unlike wild-type Ad5, the modified virus did not result in increased serum levels of liver enzymes in infected mice.
These results provide a strong preclinical proof of concept for the use of miR122 target sites for reducing the risk of liver
damage caused by oncolytic adenoviruses, and suggest that ectopic miR122 target elements should be considered as an
additional safety measure included in any therapeutic virus or viral vector posing potential hazard to the liver.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNA molecules
20–24 bp in length that negatively regulate gene expression
through binding to complementary sequences typically residing
within the 39 un-translated region (UTR) of mRNAs. Partial
sequence complementarity between miRNA and the target
mRNA leads to repression of mRNA translation, whereas a high
degree of sequence complementarity can guide destruction of the
target mRNA [1]. Already more than 1000 human miRNA
precursor sequences have been deposited in miRBase [2], and
more than 50% of cellular mRNAs have been estimated to be
under miRNA regulation [3,4]. miRNAs are expressed in tissue-
and differentiation state-specific patterns, and are often differen-
tially expressed or deleted in various human cancers [5,6,7].
Several viruses infecting humans have been shown to contain
target sequences for human miRNAs that can suppress viral gene
expression [8,9], but the role of this phenomenon as an antiviral
mechanism remains controversial [10]. Nevertheless, numerous
recent studies have shown that by introducing artificial miRNA
target elements into viral genomes the miRNA machinery can be
experimentally exploited to modify the replicative tropism of both
RNA and DNA viruses (reviewed by Kelly and Russell [11]. By
preventing replication in specific tissues accounting for viral
pathogenicity it is possible to generate live attenuated vaccine
viruses, as well as safer oncolytic viruses for the treatment of
cancer. For example, Barnes at al. used a miRNA targeting
strategy to control poliovirus tissue tropism for developing
rationally attenuated polio vaccines [12]. By inserting target sites
for muscle-specific miRNAs into the viral genome Kelly et al. were
able to overcome the lethal myositis occurring in tumour bearing
mice infected with Coxsackie A21 virus without compromising the
oncolytic potential of this virus [13].
Adenoviruses have been actively studied as tools for cancer
virotherapy [14,15,16]. Several approaches have been used to
increase tumour selectivity of oncolytic adenoviruses. Chemical or
genetic modifications of capsid proteins have been made to
augment infection of cancer cells [17]. Replacement of the E1A
promoter with tumour- or tissue-specific promoters has been used
to target adenovirus replication into tumours, such as prostate
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carcinoma [18]. In addition, removal of the E1B55K reading
frame as well as specific deletions within E1A have been used to
increase tumour selectivity of adenovirus replication [19].
Systemic administration of adenoviruses leads to infection of
hepatocytes, which can cause severe liver toxicity [20,21]. To
improve the safety of oncolytic adenoviruses we have introduced a
miRNA-based approach for engineering adenoviruses that are
suppressed in their replication by the liver-specific miR122 [22].
By inserting miR122 target elements in the 39UTR of E1A gene
we could strongly reduce E1A expression in cells of hepatic origin.
Subsequently, Cawood at al. used the same strategy to show
reduced E1A protein levels in murine liver in vivo as well as in
cultured human hepatocytes in vitro [23,24]. However, in order to
achieve potent liver-specific suppression of adenovirus replication
additional E1A expression-reducing modifications have been
necessary [22,25].
Thus, it has remained unclear if miRNA-based engineering
alone has the potential to prevent liver toxicity associated with
systemic administration of oncolytic adenoviruses. In this study we
show in normal human liver tissue strong suppression of otherwise
unmodified adenovirus 5 carrying six copies of miR122 target
elements in E1A 39 UTR. These results provide a definitive
validation for introducing miR122 targets into oncolytic adeno-
virus constructs as a safeguard of the liver.
Results
Construction and Characterization of a Novel miRNA-
targeted Adenovirus
To generate a miRNA-targeted version of wild-type adenovirus
5 (Ad5 in Fig. 1), we inserted six copies of target elements with
perfect sequence complementarity for the liver-specific microRNA
miR122 in the 39UTR of the E1A gene (Ad5T122 in Fig. 1). As a
control virus, we used a non-replicative virus containing the firefly
luciferase gene under the control of the cytomegalovirus (CMV)
promoter in the E1-region [26] (Ad5Luc1 in Fig. 1).
Huh7 hepatocellular carcinoma cells resemble normal hepato-
cytes in that they express significant amounts of the liver-specific
miR122 [27], and have previously been used as an in vitro model
for adenovirus infection of liver cells to demonstrate the capacity of
miR122 target sites to down-regulate E1A expression [22,23].
Thus, we infected Huh7 cells together with a panel of cancer cell
lines of non-hepatic origin with Ad5, Ad5T122 or Ad5Luc1 at a
multiplicity of infection 0.05. Because of the non-hepatic origin of
the latter cell lines they were not expected to express miR122. To
confirm this, we quantified the functional miR122 expression in
these cell lines using a previously validated dual luciferase assay
[22]. As expected, a strong miR122 target element-dependent
suppression of reporter gene expression was observed in Huh7
cells, whereas no evidence for miR122 expression in A549,
HCT116, or Hep-2 cells could be detected (Figure S1). The extent
of lytic cell killing caused by the spread of the infection in this
panel of cell lines was monitored using a colorimetric cell viability
assay (Figure 2). The E1-deleted, non-replicative Ad5Luc1 did not
have a significant effect on the viability of any of the cell lines
tested, whereas infection with Ad5 led to destruction of all cell lines
with a variable but high efficiency. Very similar cytopathicity was
observed following Ad5T122 infection in all of the non-hepatic cell
lines. By contrast, cell death caused by Ad5T122 was strongly
Figure 1. Schematic illustration of the virus constructs used in this study. Ad5 is a wild-type serotype 5 adenovirus containing an
unmodified E1 region. In Ad5T122, six copies of miR122 target elements were introduced in the 39UTR of E1A gene. Ad5Luc1 is a replication-deficient
virus in which the whole E1-region has been replaced with a CMV-driven firefly luciferase gene.
doi:10.1371/journal.pone.0054506.g001
Figure 2. Comparison of cell killing by Ad5 and Ad5T122 in a
panel of cancer cell lines. Four cell lines of non-hepatic (HCT116,
A549, and Hep-2) or hepatic (Huh7) origin were infected with Ad5Luc1
(non-replicative virus control), Ad5, or Ad5T122 at an MOI of 0.05. Cell
survival in the infected cells was measured 7 days (Hep-2 and A549) or 9
days (HCT116 and Huh7) post-infection using an ATP-based cell viability
assay, and plotted on the y-axis as the percentage of the control values
measured from uninfected cultures. The data are presented as the
mean of six repetitions 6 standard error.
doi:10.1371/journal.pone.0054506.g002
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reduced in Huh7 cells, indicating that replication of Ad5T122
could be attenuated by miR122.
To confirm that the attenuation of Ad5T122 in Huh7 cells was
indeed specifically due to silencing by miR122 we generated stable
cell lines in which the critical miRNA machinery component
Argonaute 2 (Ago2) had been targeted for silencing with
lentivirally transduced anti-Ago2 shRNAs. We also examined
the effect of miR122 inhibition by a transfected antagomir
designed against miR122. In both cases the suppressive effect of
the miR122 target elements on replication and cytopathicity of
Ad5T122 in Huh7 cells was almost completely abolished (Figure
S2).
Ad5T122 is Strongly Attenuated in Normal Human Liver
but Replicates Well in Tumour Tissue
To examine the potential of the miR122-mediated suppression
in controlling Ad5T122 replication in human liver we turned into
an experimental system based on ex vivo culturing of precision-cut
human liver tissue slices [28,29]. Since human Ad5 is normally
only capable of an abortive genome replication in murine cells
[30], we considered this ex vivo human liver infection model as a
superior study system for preclinical evaluation of adenoviral-
induced liver toxicity. Indeed, this system allowed us to follow
productive adenovirus infection in the presence of all the cell types
within the context of the normal three-dimensional architecture of
the human liver (see Figure 3).
The same ex vivo experimental system was also used to confirm
that the robust replication of Ad5T122 observed in cancer line
lines (Figure 2) could be recapitulated in human tumour tissue. To
this end, we compared the replicative capacity of Ad5 and
Ad5T122 in precision-cut tumour slices obtained from a colorectal
carcinoma liver metastasis, which is a particularly relevant
malignancy for this study. Oncolytic adenoviruses have already
been evaluated in clinical trials for treatment of patients with
colorectal cancer liver metastases [31,32], and the value of
hepatocyte detargeting of the virotherapy is especially evident in
this instance.
The histomorphological evaluation based on haematoxylin and
eosin staining of the uninfected precision-cut liver slices showed
that although towards the end of the 5 day follow-up some
increase in the amount of well demarcated coagulation necrosis
was observed in the central areas of the slices, the outer cell layers
remained viable for the entire duration of the experiments (Panel J
in Fig. 3). In the precision-cut tumour slices the integrity of the
histology was preserved even better, and the majority of the cells
appeared viable after five days of ex vivo culture (Panel G in Fig. 3).
Immunohistochemical analysis of the Ad5-infected tissue slices
with an antibody against adenovirus E1A protein showed
considerable increase in signal intensity in the liver as well as in
the tumour as the infection proceeded (Figure 3, panels B and E,
and data not shown), indicating efficient viral replication and
spread in both tissues. A very similar staining pattern was observed
when immunohistochemistry was used to follow the spread of
Ad5T122 in the tumour tissue (Figure 3, panel C). This confirmed
that inclusion of the miR122 target sites had not compromised the
replicative potential of Ad5T122 in the tumour tissue, as we had
already observed in cancer cell lines (Figure 2). By contrast,
immunostaining of the Ad5T122-infected liver tissue did not
reveal any specific signal for E1A (Figure 3, panel F), and appeared
identical to the analysis of the uninfected control liver tissue
(Figure 3, panel D). Thus, we concluded that miR122 in normal
human liver tissue could exert a powerful negative regulation on
the target site-containing virus.
Immunohistochemistry of the infected tissues does not provide a
quantitative measure of viral replication, and low levels of E1A do
not exclude replication of the miR122-targeted virus. Therefore,
to directly examine the rate of productive replication of Ad5 and
Ad5T122 in the human liver and colorectal cancer liver metastasis
tissues the amount of infectious virus in the medium of these ex vivo
cultures was quantitated at different time point after the virus
inoculum. Data from titration experiments done in triplicate to
determine the tissue culture infective dose 50 (TCID50) are shown
in Figure 4. To minimize the manipulation of these tissues the
input virus (107 PFU/ml) was not removed, which thus accounted
for the infectious titre measured 1 h p.i. (0 d time point in Figs. 4A
and 4B).
The infectious titre of Ad5 in the liver tissue supernatants
increased robustly during the follow-up period, exceeding the
input dose by 68-fold at the 5d time point for liver #1 and by 27-
fold for liver #2. By contrast, very little infectious Ad5T122 was
found in the liver tissue supernatants, where the titre for liver #1
only slightly (1.3-fold) exceeded the input (1 h p.i.) level at the final
5d time point, and for liver #2 even decreased to less than half
(0.47-fold) of the original input. In samples of colorectal cancer
liver metastasis tissue both viruses replicated to the same extent
(Fig. 4B). Based on these data we conclude that the miR122 sites
could strongly suppress replication of Ad5T122 in normal human
liver tissue without compromising its replication in colorectal
cancer liver metastasis tissue.
Systemic Injection of Ad5 but not Ad5T122 Leads to
Hepatic Damage in Mice
Despite the failure of human adenovirus to productively
replicate in murine cells systemic viral injection is associated with
signs of hepatocyte damage, such as elevated serum levels of the
liver enzyme alanine aminotransferase (ALAT). To investigate the
behaviour of Ad5T122 in this mouse model of adenovirus-induced
liver toxicity we injected 16109 PFU of Ad5, Ad5T122 or PBS
into the tail vein of C57bl/6 mice. 72 h post-injection these
animals were sacrificed and serum ALAT levels were measured.
Mice injected with Ad5 showed significantly increased ALAT
levels compared to PBS injected control mice, indicating that
hepatocyte damage had indeed occurred. By contrast, mice
injected with Ad5T122 showed ALAT levels that were indistin-
guishable from those of PBS injected mice (Fig. 5).
Ad5T122 and Ad5 have Similar Oncolytic Potential in a
Lung Cancer Xenograft Model
Although Ad5T122 replicated well and was as cythopathic as
Ad5 in non-hepatic tumour cell lines (Figure 2) it was important to
confirm that its attenuation in liver was not associated with a
reduced oncolytic potential in a more relevant model of cancer
virotherapy. Therefore, groups of nude mice bearing an estab-
lished subcutaneous A549 lung cancer xenografts with initial
volumes typically ranging between 15–40 mm3 were treated
intratumourally on days 0, 2 and 4 with 16107 PFU of Ad5,
Ad5T122 or a corresponding volume of PBS, and tumour growth
was monitored for 12 days following the start of the treatment.
The group of mice receiving PBS showed rapidly increasing
tumour growth, and by day 12 after the start of the treatment the
average volume of the tumours had reached more than 56 the
initial volume. The groups of mice receiving either Ad5 or
Ad5T122 showed very similar oncolytic potential and significantly
reduced tumour growth from day 8 compared to the PBS treated
group (Fig. 6). Based on these data we conclude that the oncolytic
Efficient Adenovirus Liver-Detargeting by miR122
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potency of Ad5T122 was not reduced compared the wild-type
Ad5.
Discussion
In this study we show that targeting of E1A to cell type-specific
downregulation by miR122 is sufficient to potently attenuate
adenovirus replication in the human liver. These observations
emphasize the utility of miRNA-mediated optimization of the
tropism of virotherapy in general, and its use in liver detargeting of
oncolytic adenoviruses in particular.
Using a chimeric Ad5/3 adenovirus containing three miR122
target elements in the E1A 39UTR, we have previously reported
that despite potent suppression of E1A mRNA and protein
expression, viral replication was only modestly attenuated in the
liver-derived Huh7 cells [22]. In order to bring the replication of
this modified Ad5/3 virus effectively under the control of miR122-
Figure 3. Immunohistochemical analysis of Ad5 and Ad5T122 infection in ex vivo tissue cultures of normal human liver and
colorectal carcinoma liver metastasis. Precision-cut tumour (top and third row of panels) and liver (second row and bottom panels) tissue
cultures were left uninfected (left panels) or infected with 107 PFU (in 2 ml of media) of Ad5 (middle panels) or Ad5T122 (right panels), and fixed five
days later for staining with haematoxylin-eosin (panels G-L) or an antibody against the viral E1A protein (panels A–F). Necrosis developing in the
central area of the uninfected control tissue (panel J) is indicated with arrows.
doi:10.1371/journal.pone.0054506.g003
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mediated E1A regulation, it was necessary to combine the liver-
specific, miR122-mediated inhibition with a mutation that non-
specifically decreased E1A translation in all cell types. By itself this
uniform decrease of E1A protein production did not have a
noticeable effect on Ad5/3 replication in a panel of non-hepatic
cancer cell lines, but together with the miR122-mediated E1A
control led to a potent suppression of replication and cytopathicity
in Huh7 cells [22].
Subsequently Cawood et al. reported the use of a serotype 5
virus in which E1A had been replaced with an E1A-luciferase
fusion gene containing four miR122 target elements in its 39UTR.
This chimeric mRNA was strongly downregulated by miR122, as
evidenced by reduced luciferase activity in Huh7 cells and in
primary hepatocyte cultures, as well as in the livers of infected
mice. They also showed that serum markers of liver damage as
well as viral genome copy numbers in the livers of mice infected
with wild-type Ad5 containing four miR122 targets were lower
than mice infected with an unmodified virus [23,24]. While
promising, it is difficult to extrapolate these findings to the
infection of human liver, since human adenoviruses are not able to
productively replicate in mouse cells [30]. Nevertheless, it is
interesting to note that despite this limited capacity to replicate in
murine cells, our current findings together with the data by
Cawood et al. clearly show that the elevated markers of liver
damage in mice are a genuine consequence of adenoviral gene
expression in hepatocytes rather than due to less direct hepato-
toxicity caused by the viral particles, and can thus be counteracted
by miR122-based targeting.
Cawood et al. suggested that four miR122 target sites as
compared to the three copies used in our previous study allowed a
better control of viral replication. However, no data was provided
on infection of Huh7 or other liver-derived cells that would be
competent for adenovirus replication. On the other hand, similar
to our earlier study, Leja et al. reported that combining miR122-
mediated E1A mRNA suppression with other inhibitory measures
was required to potently suppress adenovirus replication in
cultured hepatic cells [25]. Specifically, they combined miR122-
mediated downregulation of E1A with deletion of the E1B gene
and a tissue-specific promoter showing low activity in the liver to
drive E1A transcription.
Figure 4. Quantitative analysis of productive replication of Ad5 and Ad5T122 in human liver and in liver metastatic colorectal
cancer tissue. (A) Titration of infectious virus in the supernatants of liver tissue cultures collected 1 h (0d), 1d, 3d, or 5d after infection with 107 PFU
of Ad5 or Ad5T122. (B) Infectious titre in supernatants of the tumour tissue infected with 107 PFU of Ad5 or Ad5T122 were quantitated 5 d after the
infection. The virus titres are indicated as the tissue culture infective dose 50 (TCID50) on the y-axis. The data are presented as the mean of triplicates
6 standard error.
doi:10.1371/journal.pone.0054506.g004
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The potent suppression of the current Ad5T122 virus in the
normal human liver tissue may be contributed by the higher
number of miR122 targets compared to the Ad5/3-derived virus
that we have studied earlier [22] (six vs. three copies). However,
Leja et al. also used six miR122 targets in their related study
design discussed above. Moreover, while Ad5T122 was clearly
more attenuated in Huh7 cells than our previous Ad5/3-derivative
[22], residual replication/cytopathicity was still observed in the
Ad5T122-infected Huh7 cells (see Figure 2). Thus, the profound
attenuation of Ad5T122 observed in the ex vivo cultured human
liver (Figure 4A) was likely related to the non-transformed
phenotype and the normal tissue environment of the hepatocytes
in the ex vivo tissue culture. Indeed, E1A provides several key
functions for adenovirus replication, which are differentially
needed in normal vs. transformed cells [33]. Interactions of E1A
with host cell proteins, such as the tumour suppressor Rb,
modulate the activity of transcription factors and cell-cycle
regulators, thereby promoting further viral gene expression and
pushing the host into the S-phase of cell cycle to enable viral DNA
replication. Since these signalling pathways are inherently
deregulated in transformed cells [34], such as Huh7, adenovirus
replication may proceed normally even if the E1A levels are
greatly reduced [22,35]. On the other hand, although the rate of
proliferation of primary hepatocytes grown on cell culture dishes
depend on many factors, such culturing effectively promotes the
transition of their cell cycle towards the S-phase [36,37]. Thus,
although representing a more physiological study system than the
Huh7 hepatocarcinoma cell line, cultured primary hepatocytes do
not provide a good model for addressing the effects of suppressed
E1A expression on adenovirus replication in the liver. Finally, it is
also important to note that Huh7 cells express only 8% of the
miR122 levels observed in primary human hepatocytes [27].
Indeed, miR122 is very highly expressed in normal hepatocytes
where it has been estimated to constitute over 70% of all miRNAs
expressed [27,38]. Equally important, miRNA122 is one the most
tissue-specific miRNA and apart from minimal expression in some
cells of the thymus and brain, it is not expressed outside of the liver
[38,39,40,41].
Although even a strong systemic antagomir-mediated miR122
inhibition used as an experimental HCV therapy did not show any
obvious adverse effects on the liver [42], the prominent role of
miR122 in hepatocytes might raise concerns of disrupting normal
gene regulation in hepatocytes due to a ‘‘sponge effect’’ of
expression of multiple miR122 target sites. However, this is not a
relevant concern in our approach because of a strong inbuilt
negative feedback loop in the Ad5T122 virus. The number of
miR122 target elements is determined by the copy number of E1A
mRNAs in the infected cells, which becomes very low in liver cells
due to miR122-guided destruction. Moreover, the failure of
Ad5T122 to replicate and spread in the liver cells provides another
layer of protection against deregulating normal miR122-regulated
processes in the liver.
The success in using miR122 targets for suppressing E1A
expression, suggests that similar strategies might also be useful for
preventing potentially harmful replication of other therapeutic or
vaccine viruses. Moreover, miR122-control could also be further
employed in liver detargeting of oncolytic adenoviruses by placing
additional target sequences in other positions in the viral genome.
Compared to E1A, targeting of an mRNA encoding for a
structural viral protein might result in a potent attenuation even if
a less complete shut-off of the target gene expression would be
achieved. Conversely, however, maximal replication in tumour
cells might be compromised even by minor reduction in the levels
of the modified mRNA, which is not a concern in the case of E1A.
It has been reported that viral sequestration into the liver and
subsequent infection of the hepatocytes following systemic
administration of serotype 5 adenoviruses can be reduced by
introducing mutations into the Ad5 hexon protein that abolish
binding of the viral capsid to the blood coagulation factor X (FX)
[43,44]. Combining such transductional liver-detargeting with the
post-transcriptional, miR122-based approach validated in this
study would be straight-forward, and could further minimize the
potential damage to hepatocytes by oncolytic adenoviruses,
especially when treating tumours outside of the liver.
Figure 5. Assessment of hepatotoxicity of Ad5 and Ad5T122
systemically administered into mice. Measurement of serum ALAT
levels 72 h after systemic injection of 109 PFU of Ad5, Ad5T122 or PBS
(Mock). Data are presented as mean 6 standard error. Four animals per
group were used.
doi:10.1371/journal.pone.0054506.g005
Figure 6. Oncolytic potential of Ad5T122 and Ad5 in a lung
cancer xenograft model. Mice were treated with 107 PFU of Ad5,
Ad5T122, or injected with a corresponding volume of PBS (Mock) on
days 0, 2 and 4, as indicated by arrows. Tumour size was calculated as
the volume of an ellipsoid. Tumour growth is expressed as a percentage
increase from first day of virus injection. The asterisks (*) indicate a
statistically significant differences in the volumes of the PBS-injected
tumours compared to the virus-treated tumours. The number of
tumours in each group were 10 (PBS), 11 (Ad5T122), and 12 (Ad5). Data
are presented as mean 6 standard error.
doi:10.1371/journal.pone.0054506.g006
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Of note, when considering intrahepatic tumours, the value of
miR122-based targeting is not limited to metastatic disease, but
could also be exploited in virotherapy of primary hepatocellular
carcinoma (HCC). Reflecting its role as a tumour suppressor
[45,46], the loss of miR122 expression is common in HCC
[47,48], and the Huh7 cells used in this study are exceptional
among HCC-derived cell lines in resembling normal hepatocytes
by expressing miR122 [27].
It seems likely that the future oncolytic adenoviruses to be used
in the clinics will be ‘‘armed viruses’’ that express at least one
additional gene product aimed at enhancing direct or immune-
mediated killing of the infected cells, and promoting the
development of systemic anti-tumour immunity [14,49]. Prevent-
ing the expression of such potentially dangerous effector genes in
hepatocytes might be even more critical than suppressing viral
replication itself. Thus, placing these toxic or immunomodulatory
genes under a dual miR122 control by targeting their mRNAs
directly as well as indirectly (via miR122-regulated replication)
would provide a synergistic and powerful strategy for excluding
their expression in hepatocytes.
In summary, the current study provides a definitive proof of
concept and preclinical validation for the use of miR122 target
elements for reducing the risk of liver toxicity of therapeutic
adenoviruses. Our data show that in normal human liver tissue
miR122 target elements alone are sufficient to profoundly
attenuate Ad5. However, due to the ease of introduction and
the small genomic size of this modification, it should be possible
and beneficial to combine it with any other adenoviral targeting
approach.
Materials and Methods
Ethics Statement
Human tissue specimens were obtained with written informed
consent and approval by ethics committee of the Helsinki
University central hospital. All animal experiments were approved
by the experimental animal committee of the University of
Helsinki and the provincial government of Southern Finland.
Cell Lines
Human lung carcinoma cell line A549, human colorectal cancer
cell line HCT116 and human epidermoid carcinoma cell line
HEp-2 was obtained from ATCC (Manassas, VA). Human
embryonic kidney cell line 293 was purchased from Microbix
(Toronto, Canada). Human hepatocellular carcinoma cell line
Huh7 [50] was a gift from Professor Mark Harris (Leeds
University, UK). All cell lines were cultured in DMEM with
10% foetal calf serum (FBS) (Life Technologies) 1% L-glutamine
and 1% penicillin/streptomycin at 37uC/5% CO2.
Dual-luciferase Assays
Cells were transfected with Renilla- and firefly-luciferase
plasmids as described previously [22] and 48 h post-transfection
luciferase activities were measured using Dual-Luciferase Assay
System (Promega).
Construction and Production of Adenoviruses
pShuttle 66122 was made as described [22], except inserting six
copies of miR122 target elements instead of three. Homologous
recombination between the modified subgenomic adenoviral
genome and pAd5-D24 [51], and generation of infectious
adenovirus stocks were done using previously described standard
procedures [22]. The titres of the purified viruses were: 2.1261012
VP/ml and 1.1261011 PFU/ml for Ad5, 1.2861012 VP/ml and
3.9861010 PFU/ml for Ad5T122 and 1.4061012 VP/ml and
4.4761010 PFU/ml for Ad5Luc1. All VP/PFU ratios were below
35 indicating good quality of the virus preparations. Intact of
miRNA target elements were verified also by sequencing analyses
of the purified viral stocks.
Virus Replication and Cell Viability Assays
Viruses were titrated by using tissue culture infective dose 50
(TCID50). Briefly, permissive 293 cells were seeded in 96-well
plates (104 cells/well) and the next day eight serial 10-fold dilutions
of purified viruses or collected supernatants were subjected to the
96-well plate. After 10 days of incubation the wells with observable
CPE were counted, and the viral titres calculated calculated by the
Ka¨rber-Spearman method [52]. Cell viability was measured using
the CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega, Fitchburg, WI), and a multi-well plate reader
(Multiskan EX; Thermo Fisher Scientific, Waltham, MA) to
determine the optical density of the reactions at 490 nm.
Argonaute 2 Knockdown Cell Lines
pLKO.1-puro-CMV-TurboGFP and two different pLKO.1-
puro-shRNA-Ago2 (The RNAi Consortium (TRC) ID numbers:
TRCN0000007865 and TRCN0000007866) expression plasmids
were transfected into 293T cells together with packaging plasmids
to generate lentiviral preparations using standard procedures.
Transduced Huh7 cells stably expressing shRNA against Argo-
naute 2 (Ago2) or a control lentiviral genome (TurboGFP) were
obtained by a selection with 2.5 mg/ml puromycin for three days.
miR122 Inhibitor Assay
Huh7 cells were transfected in 12-well plates with 200 nM
miRIDIAN miR122 inhibitor (Dharmacon) or 1.6 mg of salmon
sperm DNA as a control using Lipofectamine 2000 (Invitrogen)
and 24 h post-transfection cells were infected with 400 000 PFU of
Ad5 or Ad5T122. Cells were photographed six days later to
document the appearance of a cytopathic effect.
Ex vivo Tissue Culture and Infections
Healthy human liver or a liver metastasis of colorectal
carcinoma were obtained with written informed consent and
approval by ethics committee of the Helsinki University central
hospital. A cylinder of 8 mm in diameter was cored out of the
surgically removed tissue and sliced at approximately 300–500 mm
with a Krumdieck precision-cut tissue slicer (Alabama Research
and Development Corporation, Huntsville, AL). Tissue slices were
placed into six-well plates (1 slice/well) containing 2 ml of
William’s Medium E with 10% foetal calf serum (FBS) (Life
Technologies), 1% Glutamax-I (Life Technologies) and 1%
penicillin/streptomycin. The plates were incubated at 37uC/5%
CO2 in a humidified environment for up to 5 days. A plate rocker
was used to gently agitate the slices to ensure adequate
oxygenation and viability. Slices were infected by adding 26106
or 107 PFU of virus into the medium.
Immunohistochemistry (IHC)
Slices were fixed o/n in 10% phosphate-buffered formalin,
dehydrated, embedded in paraffin and cut into 4 mm sections. The
sections were deparaffinised, rehydrated and either stained with
haematoxylin and eosin, or prepared for immune staining by
heating the slides in Tris–EDTA (pH 9.0) buffer in a microwave
oven. Antibody against Adenovirus 5 E1A (MS 1069-P0,
Neomarkers, Thermo Fisher Scientific, 1:200 dilution) was used
as a primary antibody. Dako Envision system (Dako, Agilent
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Technologies, Santa Clara, CA) including HRP-conjugated anti-
mouse secondary antibody was used for detection. Labvision
autostainer (Thermo Fisher Scientific) was used for IHC sample
preparation.
In vivo Experiments for Assessment of Liver Toxicity
Adult 5 to 7 week old female C57bl/6 mice were systemically
infected with 16109 PFU of Ad5 or Ad5T122 by tail vein injection
(diluted in 100 ml of PBS). Control group received 100 ml of PBS. 4
animals were used in each group. After 72 h post-infection blood
was taken from mice by cardiac puncture and allowed to clot for
15 min at room temperature and spun at 1200 g for 10 min.
Serum samples were added to ALAT reagent (Thermo Fisher
Scientific) and the change in absorbance (340 nm) per minute was
monitored. Units of ALAT activity were calculated according to
manufacturer’s instructions.
In vivo Experiments for Assessment of Oncolytic Potency
Adult 5 to 7 week old female NMRI nude mice were
subcutaneously injected with 36106 A549 cells into both flanks.
Initial tumour sizes were typically 15–40 mm3. Mice were treated
on days 0, 2 and 4 by intratumoural injection at 107 PFU/tumour
with either Ad5 or Ad5T122 (diluted in 50 ml of PBS). Control
group received 50 ml of PBS. 6 animals were used in each group.
In order to determine tumour volume by hand-held calliper, the
greatest longitudinal diameter (length) and the greatest transverse
diameter (width) were determined. Tumour volumes were
calculated by the modified ellipsoidal formula [53,54]: Tumour
volume= 0.5(length6width2). MedCalc software was used to
calculate serial measurements (area under curve) for statistical
analysis. A P value of less than 0.05 was considered as significant.
Supporting Information
Figure S1 Functional quantitation of miR122 expression in
different cell lines. The indicated cells lines were co-transfected
with an unmodified Firefly luciferase vector (pSIRNALUC-
39MluI) or its derivative containing a miR122 target element in
the 39 UTR (pSIRNALUC-3916T122) together with a vector for
Renilla luciferase (pcDNA-Renilla). The average Firefly/Renilla
luciferase activity ratios in these cells 48 hours after transfection is
shown on the y-axis. The value from pSIRNALUC-39MluI -
transfected cells was set to 100%, and the ratio from pSIRNA-
LUC-3916T122 -transfected cells is expressed relative to this. The
data are presented as the mean of triplicates 6 standard error.
(TIF)
Figure S2 Suppression of Ad5T122 replication in Huh7 cells is
miR122-specific. A. Effect of miRNA machinery disruption by
down-regulation of Argonaute 2 on Ad5T122 replication in Huh7
cells. Two independent Huh7 cell lines (Ago2-kd1 and Ago-kd2)
stably expressing different shRNA constructs targeting Ago2 or a
control Huh7 derivative cell line (Control) transduced with a
control lentiviral vector were infected with 400 000 pfu of Ad5 or
Ad5T122, or left uninfected as indicated, and photographed 6
days post-infection. B. Effect of miR122 inhibition by a synthetic
antagomir oligonucleotide on Ad5T122 replication in Huh7 cells.
Cells were transfected with the miR122 inhibitor or mock
transfected, infected with 400 000 PFU of Ad5 or Ad5T122 on
the next day, and photographed 6 days post-infection.
(TIF)
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